Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR5 | P32302 | 3/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | BAD | Q92934 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | THRA | P10827 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7408640 | 0.97 | TRPA1 (0.49) | CXCR5TRPA1MEN1KMT2AL3MBTL1 | |
| SCHEMBL31305927 | 0.97 | TRPA1 (0.49) | CXCR5TRPA1MEN1KMT2AL3MBTL1 | |
| Methyl Benzoate SCHEMBL29069397 | 0.81 | TSHR (0.50) | CXCR5MEN1KMT2AL3MBTL1LMNA | |
| SCHEMBL12930758 | 0.81 | CXCR5 (0.46) | CXCR5MEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL29069369 | 0.80 | SMN1; SMN2 (0.56) | MEN1KMT2AL3MBTL1ALDH1A1LMNA | |
| SCHEMBL4570298 | 0.80 | BCL2L1 (0.52) | CXCR5MEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL31359858 | 0.80 | BCL2L1 (0.52) | CXCR5MEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL11855241 | 0.80 | TRPA1 (0.60) | TRPA1KMT2AALDH1A1LMNATSHR | |
| SCHEMBL24170576 | 0.80 | PSMB5 (0.58) | CXCR5MEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL13728618 | 0.80 | PTPRC (0.48) | TRPA1MEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10043978-B2 | Organic semiconductor formulations | FLEXTERRA, INC. (US) | 2018-08-07 | — | — | US | claimed |
| US-20170012208-A1 | ORGANIC SEMICONDUCTOR FORMULATIONS | USINVEST LLC | 2017-01-12 | — | — | US | claimed |
| WO-2024126650-A1 | NOVEL BICYCLIC-CARBOXAMIDE COMPOUNDS USEFUL AS PESTICIDES | SYNGENTA CROP PROTECTION AG (CH) | 2024-06-20 | — | — | WO | disclosed |
| CN-108699098-B | C-glucoside derivative having fused benzene ring or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition comprising same | 第一药品株式会社 | 2022-01-25 | — | — | CN | disclosed |
| US-10752604-B2 | C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same | Je II Pharmaceutical Co., Ltd. (KR) | 2020-08-25 | — | — | US | disclosed |
| US-10752604-B2 | C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same | Je II Pharmaceutical Co., Ltd. (KR) | 2020-08-25 | — | — | US | disclosed |
| EP-3404033-B1 | C-GLUCOSIDE DERIVATIVE CONTAINING FUSED PHENYL RING OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | JEIL PHARMACEUTICAL CO LTD (KR) | 2020-08-05 | — | — | EP | disclosed |
| US-20190002425-A1 | C-Glucoside Derivative Containing Fused Phenyl Ring or Pharmaceutically Acceptable Salt Thereof, Process for Preparing Same, and Pharmaceutical Composition Comprising Same | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2019-01-03 | — | — | US | disclosed |
| US-20190002425-A1 | C-Glucoside Derivative Containing Fused Phenyl Ring or Pharmaceutically Acceptable Salt Thereof, Process for Preparing Same, and Pharmaceutical Composition Comprising Same | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2019-01-03 | — | — | US | disclosed |
| EP-3404033-A1 | C-GLUCOSIDE DERIVATIVE CONTAINING FUSED PHENYL RING OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Jeil Pharmaceutical Co., Ltd. (KR) | 2018-11-21 | — | — | EP | disclosed |
| US-10043978-B2 | Organic semiconductor formulations | FLEXTERRA, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| WO-2017119700-A1 | C-GLUCOSIDE DERIVATIVE CONTAINING FUSED PHENYL RING OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 제일약품주식회사 | 2017-07-13 | — | — | WO | disclosed |
| US-20170012208-A1 | ORGANIC SEMICONDUCTOR FORMULATIONS | USINVEST LLC | 2017-01-12 | — | — | US | disclosed |
| US-9293711-B2 | Organic semiconductor formulations | POLYERA CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-20140042369-A1 | Organic Semiconductor Formulations | USINVEST LLC | 2014-02-13 | — | — | US | disclosed |
| US-20050182269-A1 | Process for the preparation of 3-cyano-1-naphthoic acid and some analogues thereof | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | US | disclosed |
| CN-1653019-A | Process for preparing methyl-substituted aromatic compounds | NEW JAPAN CHEM CO LTD (JP) | 2005-08-10 | — | — | CN | disclosed |
| EP-1517884-A1 | A PROCESS FOR THE PREPARATION OF 3-CYANO-1-NAPHTHOIC ACID AND SOME ANALOGUES THEREOF | AstraZeneca AB (SE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004000792-A1 | A PROCESS FOR THE PREPARATION OF 3-CYANO-1-NAPHTHOIC ACID AND SOME ANALOGUES THEREOF | ASTRAZENECA AB (SE) | 2003-12-31 | — | — | WO | disclosed |
| CN-1055179-A | Novel 8-sulphonamide methylene radical-2-amino-1,2,3,4-tetralin | MERRELL DOW PHARMA (US) | 1991-10-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182269-A1 | Process for the preparation of 3-cyano-1-naphthoic acid and some analogues thereof | CYP8B1, CYP51A1, NISCH | CXCR5 3372/4885TRPA1 3532/4885MEN1 1011/4885 |
| US-20190002425-A1 | C-Glucoside Derivative Containing Fused Phenyl Ring or Pharmaceutically Acceptable Salt Thereof, Process for Preparing Same, and Pharmaceutical Composition Comprising Same | SLC5A2, SLC5A1, UGGT1 | CXCR5 3569/4885TRPA1 2493/4885MEN1 4596/4885 |
| US-10752604-B2 | C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same | SLC5A2, SLC5A1, UGGT1 | CXCR5 3569/4885TRPA1 2493/4885MEN1 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.